Biography
Jeffrey regularly advises major pharmaceutical companies in connection with licensing and collaboration agreements and manufacturing and supply arrangements. He has been involved with numerous transactions involving novel therapeutic modalities, including genetic medicine and AI-assisted target and drug discovery. Jeffrey also regularly leads the technology and intellectual property aspects of major corporate transactions, including commercial arrangements associated with such transactions; and advises on the treatment of intellectual property matters in bankruptcy cases.
Jeffrey is ranked Band 1 for Technology in New York and is recognized as a leading lawyer for Technology in the U.S. by Chambers USA, where clients note he is “by far the premier licensing and collaboration attorney in the country" and “a fierce advocate for his clients, equipped with an arsenal of industry-specific knowledge." Jeffrey is recognized as a “Leading Lawyer” for Media, Technology and Telecoms: Technology Transactions by Legal 500 US. He is also recommended for Patents: Licensing, Technology Transactions, Media and Entertainment: Transactional and Healthcare: Life Sciences by Legal 500 US. Jeffrey is recognized as an “IP Star” for IP Transactions and Trademarks by Managing Intellectual Property and a “Life Sciences Star” by LMG Life Sciences Guide. Jeffrey is also recognized as a “Best Lawyer” for Information Technology Law and Technology Law in New York by Best Lawyers in America* 2024 and was named “Lawyer of the Year” for Technology Law in New York by Best Lawyers in America* 2024, 2022 and 2020. Jeffrey was shortlisted as “Practitioner of the Year (IP Transactions)” for Managing Intellectual Property’s 2022 Americas Awards. He is recognized as a “Global Leader” in New York by IAM Global Leaders and is “Highly Recommended” by IAM Patent 1000, where clients have noted he has “a stellar ability to see the forest through the trees, is a clear and concise draftsman and a constructive negotiator,” and he is “the kind of sophisticated IP lawyer you need on a tough deal – he understands his clients’ industry and business, and fights hard while communicating clearly in negotiations to get to a resolution.” He is also included in 2025 “500 Leading Dealmakers in America” list by Lawdragon and named a 2016 Technology “MVP” by Law360.
* Best Lawyers (in America) is by Levine Leichtman Capital Partners
Awards and Recognition, Speaking Engagements, Firm News & Announcements
Awards and Recognition
- Jeffrey Osterman Ranked Band 1 for Technology in New York Award Brief — Chambers USA
- Jeffrey Osterman Named a “Leading” Lawyer for Technology in the U.S. Award Brief — Chambers USA
- Jeffrey Osterman Named a “Leading” Lawyer for Media, Technology and Telecoms: Technology Transactions Award Brief — Legal 500 US
- Jeffrey Osterman Recommended for Healthcare: Life Sciences Award Brief — Legal 500 US
- Jeffrey Osterman Named “Lawyer of the Year” for Technology Law in New York Award Brief — Best Lawyers in America 2024, 2022, 2020 (Best Lawyers (in America) is by Levine Leichtman Capital Partners)
- Jeffrey Osterman Named a “Best Lawyer” for Information Technology Law and Technology Law in New York Award Brief — Best Lawyers in America 2024 (Best Lawyers (in America) is by Levine Leichtman Capital Partners)
- Jeffrey Osterman Named an "IP Star" for IP Transactions and Trademarks in New York Award Brief — Managing Intellectual Property IP Stars
- Jeffrey Osterman Recognized as a “Life Sciences Star” Award Brief — LMG Life Sciences Guide
Speaking Engagements
-
Opportunities and Obstacles: Addressing Generative AI in Corporate Transactions
Speaker(s):
Charan J. Sandhu,
Jeffrey D. Osterman,
Olivia J. Greer and
Dennis F. Adams III
March 13, 2024 — New York, NY — Charan Sandhu and Jeffrey Osterman, Co-Heads of Weil’s Technology & IP Transactions practice, along with partners Olivia Greer and Dennis Adams, moderated a panel discussion during Weil’s Technology, IP & Media Seminar Series entitled, “Opportunities and Obstacles: Addressing Generative AI in Corporate Transactions.” Among the topics discussed were best practices for modernizing due diligence to identify AI risks at transactional targets, anticipating and drafting for regulatory and litigation liabilities, and drafting deal terms to protect buyers from AI risks.
Firm News & Announcements
- Weil Advises Astorg in $282M Take-Private Acquisition of Hamilton Thorne and Concurrent Acquisition of Cook Medical Reproductive Health Deal Brief — December 03, 2024
- Four Weil Partners Named in IAM Global Leaders 2025 Firm Announcement — October 29, 2024
- Twenty-Eight Weil Partners Named to 2025 Lawdragon 500 Leading Dealmakers in America List Firm Announcement — October 21, 2024
- Weil Highly Ranked in 2024 Managing Intellectual Property IP Stars Firm Announcement — October 03, 2024
- Weil Advises WTW in $632M Sale of TRANZACT to GTCR and Recognize Deal Brief — October 01, 2024
- Weil Achieves High Rankings in 2024 LMG Life Sciences Guide Firm Announcement — September 23, 2024